Optimize Financial Inc Invests $554,000 in Trevi Therapeutics, Inc. $TRVI

Optimize Financial Inc acquired a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 60,599 shares of the company’s stock, valued at approximately $554,000.

A number of other large investors have also added to or reduced their stakes in TRVI. Russell Investments Group Ltd. boosted its holdings in Trevi Therapeutics by 194.5% in the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after acquiring an additional 2,996 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Trevi Therapeutics by 15,969.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company’s stock worth $48,000 after purchasing an additional 8,783 shares in the last quarter. Strs Ohio bought a new position in Trevi Therapeutics in the 1st quarter worth about $52,000. Catalyst Funds Management Pty Ltd purchased a new stake in Trevi Therapeutics during the 2nd quarter valued at about $56,000. Finally, Rafferty Asset Management LLC bought a new stake in Trevi Therapeutics during the 2nd quarter valued at about $60,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Morgan Stanley increased their target price on Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a report on Friday, January 9th. Stifel Nicolaus upped their price target on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, D. Boral Capital reissued a “buy” rating and issued a $19.00 target price on shares of Trevi Therapeutics in a research report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.10.

Trevi Therapeutics Stock Performance

TRVI stock opened at $11.48 on Wednesday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -31.03 and a beta of 0.94. The business’s 50-day moving average is $12.02 and its two-hundred day moving average is $10.10. Trevi Therapeutics, Inc. has a fifty-two week low of $3.77 and a fifty-two week high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. Equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.